Generic and biosimilar companies used to have one venue to attack a brand patent: federal district court, under a clear-and-convincing-evidence […]

DISH Technologies LLC v. MW Media (SC), SC|2:26-cv-00508: Litigation Summary, Claims, and IP Risk Analysis DISH Technologies LLC v. MW

DISH Technologies L.L.C. v. DAZN US LLC (1:26-cv-00604): Litigation Summary, Claims Likely at Issue, and IP/Business Risk Analysis What is

DISH Technologies LLC v. Fenix International Limited (2:26-cv-00547): Litigation Summary, Claims, and Outcome Scenarios DISH Technologies LLC sued Fenix International

AbbVie v. Annora Pharma Private Limited (1:26-cv-00688): litigation status, claims at issue, and Paragraph IV/ANDA risk mapping What is AbbVie

Vertex Pharmaceuticals v. MSN Pharmaceuticals (1:26-cv-00306): Litigation Summary, Claims at Issue, and Near-Term Patent/ANDA Exposure Vertex Pharmaceuticals Incorporated sued MSN

Litigation Summary and Analysis: Novartis Pharmaceuticals Corporation v. Cipla USA Inc. (D.N.J.) | Case No. 1:26-cv-00272 Executive summary. The action

Litigation summary and analysis: Boehringer Ingelheim Pharmaceuticals Inc. v. Ridhisidhi PLLC, 1:26-cv-00372 Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) sued Ridhisidhi PLLC

Ultragenyx Pharma v. Navinta 2:26-cv-03585: Litigation Summary, Claims, and Business Impact Executive summary: The case Ultragenyx Pharmaceutical Inc. v. Navinta